A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3581-3588

  Galsky, Matthew D ^a,e   Vogelzang, Nicholas J ^a   Conkling, Paul ^b   Polzer, John ^c   Roberson, Stephanie ^c   Stille, John R ^c   Saleh, Mansoor ^d   Thornton, Donald ^c  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Virginia Oncology Associates   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Georgia Cancer Specialists   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; LY 2510924; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR CXCR4; CYCLOPEPTIDE; LY2510924;

ADULT; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER FATIGUE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; HUMAN CELL; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; YOUNG ADULT; AGED; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PEPTIDES, CYCLIC; RECEPTORS, CXCR4; TREATMENT OUTCOME;

EID: 84903843801     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2686     Document Type: Article

References (30)

1. Christofori G. New signals from the invasive front. Nature 2006;441: 444-50.
2. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004;14: 181-5.
3. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003;17: 792-803.
4. Hwang JH, Chung HK, Kim DW, Hwang ES, Suh JM, Kim H, et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003;88: 408-16.
5. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62: 5930-8.
6. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14: 171-9.
7. Peng S-B, Peek V, Zhai Y, Paul DC, Lou Q, Xia X, et al. Akt Activation, but not Extracellular Signal-Regulated Kinase Activation, Is Required for SDF-1α/CXCR4-Mediated Migration of Epitheloid Carcinoma Cells. Mol Cancer Res 2005;3: 227-36.
8. Ishii T, Nishihara M, Ma F, Ebihara Y, Tsuji K, Asano S, et al. Expression of stromal cell-derived factor-1/pre-B cell growth-stimulating factor receptor, CXC chemokine receptor 4, on CD34+ human bone marrow cells is a phenotypic alteration for committed lymphoid progenitors. J Immunol 1999;163: 3612-20.
9. Nanki T, Lipsky PE. Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J Immunol 2000;164: 5010-4.
10. Suzuki Y, Rahman M, Mitsuya H. Diverse transcriptional response of CD4(+) T cells to stromal cell-derived factor (SDF)-1: cell survival promotion and priming effects of SDF-1 on CD4(+) T cells. J Immunol 2001;167: 3064-73.
11. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107: 1761-7.
12. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121: 335-48.
13. Faber A, Roderburg C, Wein F, Saffrich R, Seckinger A, Horsch K, et al. The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J Biomed Biotechnol 2007;2007: 26065.
14. Drenckhan A, Kurschat N, Dohrmann T, Raabe N, Koenig AM, Reichelt U, et al. Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J Surgical Res 2013;182: 250-6.
15. Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 2011;129: 225-32.
16. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surgical Res 2009;155: 231-6.
17. Singh B, Cook KR, Martin C, Huang EH, Mosalpuria K, Krishnamurthy S, et al. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis 2010;27: 233-40.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92: 205-16.
19. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, et al. Rapid mobilization of CD34+cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22: 1095-102.
20. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000;17: 1278-83.
21. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102: 2728-30.
22. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106: 1867-74.
23. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37: 1253-62.
24. Wehler TC, Graf C, Biesterfeld S, Brenner W, Schadt J, Gockel I, et al. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease. J Oncol 2008;2008: 626340.
25. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425: 307-11.
26. Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, upregulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009;69: 7905-10.
27. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27: 3027-35.
28. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002;62: 6304-11.
29. Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003;22: 8093-101.
30. Hartmann TN, Burger M, Burger JA. The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer. J Biol Regul Homeost Agents 2004;18: 126-30.